Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions. 1986

R I Parker, and E N Forman, and K F Krumm, and M J Abeel, and H F Martin

Serum methotrexate (MTX) levels were measured in 12 children (ages 2-18 years) who received a total of 56 24-h infusions of intermediate-dose methotrexate (500 mg/m2) at 1- to 3-week intervals. Mean peak serum MTX concentration 1/2 h following a bolus of 167 mg/m2 MTX (1/3 total dose) was 25.9 X 10(-6) M, mean plateau serum MTX concentration was 7 X 10(-6) M (over 8-24 h), and mean MTX clearance was 74 ml/min/m2. No significant changes in these values were noted with increasing number of infusions, suggesting that no metabolic adaptation occurred in the manner in which the body handled the MTX when it was given repeatedly in this fashion. However, adolescent patients (greater than or equal to 15 years) demonstrated a trend toward increased MTX clearance and decreased serum MTX concentration with greater than or equal to 5 infusions. In general, toxicity was minimal and did not increase with an increasing number of infusions. Significant toxicity was found only in adolescent patients, in spite of no documented difference in either MTX serum concentrations or clearance rates between adolescent and preadolescent patients.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R I Parker, and E N Forman, and K F Krumm, and M J Abeel, and H F Martin
September 1982, Cancer treatment reports,
R I Parker, and E N Forman, and K F Krumm, and M J Abeel, and H F Martin
January 1987, Cancer drug delivery,
R I Parker, and E N Forman, and K F Krumm, and M J Abeel, and H F Martin
January 1989, Cancer chemotherapy and pharmacology,
R I Parker, and E N Forman, and K F Krumm, and M J Abeel, and H F Martin
January 1979, Clinical and experimental pharmacology & physiology. Supplement,
R I Parker, and E N Forman, and K F Krumm, and M J Abeel, and H F Martin
February 1999, General pharmacology,
R I Parker, and E N Forman, and K F Krumm, and M J Abeel, and H F Martin
January 1979, Giornale italiano di chemioterapia,
R I Parker, and E N Forman, and K F Krumm, and M J Abeel, and H F Martin
December 1978, British journal of clinical pharmacology,
R I Parker, and E N Forman, and K F Krumm, and M J Abeel, and H F Martin
January 2012, British journal of clinical pharmacology,
R I Parker, and E N Forman, and K F Krumm, and M J Abeel, and H F Martin
January 1979, Cancer chemotherapy and pharmacology,
R I Parker, and E N Forman, and K F Krumm, and M J Abeel, and H F Martin
January 1983, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!